Figure 8 Investment Strategies LLC Has $2.03 Million Stock Position in GSK PLC Sponsored ADR $GSK

Figure 8 Investment Strategies LLC increased its holdings in shares of GSK PLC Sponsored ADR (NYSE:GSK) by 90.5% in the second quarter, according to its most recent disclosure with the SEC. The firm owned 38,686 shares of the pharmaceutical company’s stock after purchasing an additional 18,380 shares during the period. GSK accounts for approximately 1.8% of Figure 8 Investment Strategies LLC’s holdings, making the stock its 20th largest position. Figure 8 Investment Strategies LLC’s holdings in GSK were worth $2,028,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also bought and sold shares of the company. Elyxium Wealth LLC acquired a new position in GSK during the fourth quarter worth approximately $30,000. Triumph Capital Management acquired a new stake in shares of GSK in the third quarter valued at approximately $40,000. Trust Co. of Vermont acquired a new stake in shares of GSK in the second quarter valued at approximately $54,000. Philadelphia Investment Partners LLC bought a new position in shares of GSK during the 2nd quarter worth approximately $70,000. Finally, Ancora Advisors LLC bought a new position in shares of GSK during the 2nd quarter worth approximately $71,000. Institutional investors own 15.74% of the company’s stock.

Analysts Set New Price Targets

GSK has been the topic of a number of research analyst reports. Morgan Stanley restated an “underweight” rating on shares of GSK in a research note on Tuesday, August 25th. Royal Bank Of Canada reaffirmed an “outperform” rating on shares of GSK in a research report on Tuesday, June 9th. Deutsche Bank Aktiengesellschaft reiterated a “hold” rating on shares of GSK in a report on Thursday, July 30th. Jefferies Financial Group raised shares of GSK to a “strong-buy” rating in a research report on Friday, July 17th. Finally, Citigroup assumed coverage on shares of GSK in a research note on Friday, July 24th. They set a “neutral” rating for the company. One research analyst has rated the stock with a Strong Buy rating, one has assigned a Buy rating, six have assigned a Hold rating and two have assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock presently has an average rating of “Hold” and an average price target of $53.00.

Trending Headlines about GSK

Here are the key news stories impacting GSK this week:

• Positive Sentiment: GSK agreed to license exclusive rights outside Mainland China, Hong Kong, Macau and Taiwan to Hutchmed’s experimental KRAS-EGFR antibody-drug conjugate, HMPL-A830. The deal includes a reported $110 million upfront payment and could be worth up to $1.295 billion in total milestone payments, giving GSK access to a potentially differentiated solid-tumor treatment. HUTCHMED signs licensing deal with GSK for experimental solid tumour drug
• Positive Sentiment: Deutsche Bank said GSK’s Phase II mRNA flu vaccine results closely track data from Moderna’s comparable candidate. The read-through supports the credibility of GSK’s vaccine platform and could strengthen expectations for a future product in the seasonal influenza market. GSK’s mRNA flu vaccine data closely tracks Moderna’s
• Neutral Sentiment: Coverage also points to solid first-half growth and continued support from the licensing transaction. However, HMPL-A830 is an experimental, early-stage asset, so GSK must fund further development and still faces clinical, regulatory and commercial execution risks before the program can generate revenue. GSK stock gains support from licensing deal and solid first-half growth

GSK Price Performance

GSK stock opened at $49.88 on Friday. GSK PLC Sponsored ADR has a 12 month low of $39.29 and a 12 month high of $61.69. The stock’s 50 day moving average is $51.70 and its 200-day moving average is $53.20. The company has a current ratio of 0.82, a quick ratio of 0.52 and a debt-to-equity ratio of 0.81. The company has a market capitalization of $100.89 billion, a price-to-earnings ratio of 15.60, a PEG ratio of 1.95 and a beta of 0.35.

GSK (NYSE:GSK) last announced its earnings results on Tuesday, July 28th. The pharmaceutical company reported $1.36 earnings per share for the quarter, topping analysts’ consensus estimates of $1.27 by $0.09. The company had revenue of $11.14 billion for the quarter, compared to analyst estimates of $11.02 billion. GSK had a return on equity of 43.23% and a net margin of 14.56%.The firm’s quarterly revenue was up 5.3% compared to the same quarter last year. During the same quarter last year, the company earned $0.47 earnings per share. GSK has set its FY 2026 guidance at 4.900-5.000 EPS. Equities research analysts expect that GSK PLC Sponsored ADR will post 4.83 EPS for the current year.

GSK Increases Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Thursday, October 8th. Shareholders of record on Friday, August 14th will be given a dividend of $0.4515 per share. This represents a $1.81 annualized dividend and a yield of 3.6%. The ex-dividend date is Friday, August 14th. This is a positive change from GSK’s previous quarterly dividend of $0.44. GSK’s dividend payout ratio (DPR) is 55.63%.

GSK Profile

GSK (GlaxoSmithKline plc) is a London-headquartered, multinational pharmaceutical and healthcare company formed through the 2000 merger of Glaxo Wellcome and SmithKline Beecham. The company is dual-listed and operates globally, developing, manufacturing and commercializing prescription medicines, vaccines and specialty treatments. Over its history GSK has evolved through portfolio reshaping and strategic transactions to focus on science-led pharmaceuticals and vaccines.

GSK’s core activities include research and development of therapies and vaccines across a range of therapeutic areas, commercial manufacturing, and global marketing.